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Purpose of the study
Raltegravir (RAL) is the first marketed HIV integrase
inhibitor. It has shown considerable potency and safety in
clinical trials conducted in antiretroviral (ARV)-experi-
enced HIV+ patients. This study aims to assess the per-
formance of RAL in a routine clinical practice, as part of
therapeutic strategies besides salvage therapy.
Methods
Retrospective longitudinal assessment of all HIV+ patients
who received RAL at our institution until June 2008. Over-
all, the drug was prescribed as part of a salvage regimen or
in patients with undetectable plasma HIV-RNA under
another regimen as part of a switch strategy due to intol-
erance or toxicity to the previous combination. Data were
recorded at baseline and during 48 weeks of follow-up.
Summary of results
A total of 106 patients were analysed. Mean age 46 (± 7)
years, male 80%, IDUs 45% and MSM 35%; HBsAg+ 9%,
HCV-RNA+ 32%. Mean time on ARVs: 9.7 (± 3.7) years. In
62 patients, RAL was part of a salvage regimen, being
other active drugs (one in 56%, ≥2 in 23%): darunavir
40%, tenofovir 21%, atazanavir 10%, and etravirine 6%.
Baseline plasma HIV-RNA and CD4 counts were [median
(IQR)]: 3.8 (2.9–4.4) log10 copies/ml and 252 (156–
418) cells/μL, respectively. After 1 month, median plasma
HIV-RNA declined 1.94 log10 and 75% of patients
reached <50 copies/ml. In the 44 patients in whom RAL
was used due to convenience (n = 6), intolerance (n = 16)
or toxicity to other ARVs (n = 22), the most commonly
switched drugs were atazanavir/r (31%), T-20 (16%) and
lopinavir/r (10%). None of the 44 patients failed virolog-
ically on RAL during follow-up. CD4 counts increased a
median of 45 cells/μL.
In all 106 patients on RAL, no serious adverse events
occurred and treatment adherence was >95%; laboratory
parameters including liver enzymes and lipids did not sig-
nificantly change during follow-up.
Conclusion
Outside clinical trials, RAL shows a remarkable virological
and immunological efficacy as part of salvage regimens, as
well as in switch strategies in patients with undetectable
viremia experiencing intolerance or toxicity to other
antiretrovirals. Since the drug is safe and well tolerated, it
may be worth to consider its use in earlier HIV stages, par-
ticularly in patients with cardiovascular risk and/or viral
hepatitis. (Table 1.)
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Baseline 3 months 6 months 9 months 12 months
SALVAGE THERAPY n = 62 n = 39 n = 27 n = 21 n = 9
ΔpHIV-RNA log10 cop/mL 0 -1.8 (-2.6 – -1.2) -2.1 (-2.7 – -1.3) -2 (-2.6 – -1.2) -2.4 (-2.7 – -1.3)
%pts pHIV-RNA<50 cop/mL 0 84 85 86 67
ΔCD4+ cells/μL 0 62 (0–118) 38 (4–61) 82 (20–148) 88 (28–184)
NO SALVAGE THERAPY n = 44 n = 20 n = 10 n = 4 -
%pts pHIV-RNA<50 cop/mL 100 100 100 100 -
ΔCD4+ cells/μL 0 27 (-8 – +70) 45 (-3 – +98) 13 (-38 – +202) -
ALL PATIENTS n = 106 n = 59 n = 37 n = 25 n = 9
Hb g/dL 14.9 (13.7–15.9) 14.9 (13.8 – 16.5) 15.3 (14.2–16.3) 15.4 (14.8–16.4) 14.8 (13.2–16.3)
Glucose mg/dL 98 (92–110) 99 (91–108) 99 (91–104) 99 (92–106) 98 (91–107)
Creatinine mg/dL 0.9 (0.8–1) 0.9 (0.8–1) 0.9 (0.8–1) 0.9 (0.9–1) 0.9 (0.8–1)
AST IU/L 32 (24–50) 29 (25–41) 28 (22–51) 27 (23–34) 31 (22–43)
ALT IU/L 31 (21–62) 32 (23–46) 27 (20–61) 27 (18–39) 28 (21–68)
Total bilirubin mg/dL 0.8 (0.6–1.3) 0.7 (0.6–1) 0.8 (0.6–1.2) 0.8 (0.6–0.9) 0.8 (0.6–0.9)
Total cholesterol mg/dL 185 (147–208) 190 (160–224) 190 (171–217) 201 (176–224) 193 (154–222)
HDL cholesterol mg/dL 33 (26–43) 39 (31–47)* 38 (31–48) 36 (30–44) 33 (28–42)
LDL cholesterol mg/dL 119 (86–132) 124 (84–146) 124 (106–147) 134 (112–147) 137 (104–157)
Triglycerides mg/dL 120 (71–198) 122 (91–163) 136 (69–175) 137 (102–208) 120 (63–143)
All values are expressed as median (IQR), unless otherwise indicated. *p < 0.05 compared to baseline.Page 2 of 2
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